AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Source link
AbbVie Revenue Rises on Immunology Growth
Date:
More like thisRelated
Gael Monfils honored, puts on show in final French Open match
May 25, 2026, 07:25 PM ETPARIS -- In front...
U.S. military says it conducted strikes against targets in Iran
The U.S. military struck targets in Iran near the...
Thousands enjoy Memorial Day weekend at Elephant Butte despite lower turnout and water levels
ELEPHANT BUTTE, N.M. (KRQE) – Low water levels once...